Published by Piel con Maria · skinscan.guide

Melasma Affects 50% of Women in Tropical Climates — Why Most Treatments Make It Worse

The brown patches appeared during pregnancy. Your doctor said they’d fade. It’s been three years.

You’ve tried brightening serums. You’ve tried over-the-counter hydroquinone. A friend recommended a chemical peel. The patches lightened for two weeks, then came back darker. You’re starting to wonder if anything actually works.

Here’s what most women don’t know: with melasma, the wrong treatment doesn’t just fail — it actively makes the condition worse.

Ana’s Three-Year Battle With Patches That Wouldn’t Fade

Ana lives in Panama City. The melasma started during her second pregnancy — symmetrical brown patches across her forehead and upper lip. Her OB-GYN told her it was common, hormonal, and would likely resolve after delivery.

It didn’t. Eighteen months postpartum, the patches were still there. Frustrated, she bought a 4% hydroquinone cream from a pharmacy and used it daily. For three weeks, the patches faded noticeably. She was hopeful. Then she ran out, and within a month, the melasma came back darker than before — a phenomenon dermatologists call rebound hyperpigmentation.

A coworker suggested a glycolic acid peel. Ana went to a local spa. The peel burned more than expected, and over the following weeks, the treated areas darkened significantly. She had triggered post-inflammatory hyperpigmentation on top of the melasma — now dealing with two conditions instead of one.

It was only when she consulted a dermatologist specializing in pigmentary disorders that she learned why her approach had been counterproductive. Melasma requires a fundamentally different treatment strategy than other types of dark spots — and the aggressive treatments that work on PIH or sun damage can cause melasma to flare.

What Makes Melasma Different From Other Dark Spots

Melasma isn’t just pigmentation — it’s a chronic condition involving overactive melanocytes, increased vascularity, and a damaged skin barrier. Melasma involves both epidermal and dermal components, which is why surface-level treatments often fail. The 2025 Latin American Consensus — led by Dr. Jorge Ocampo-Candiani (UANL, Mexico) with contributions from Dr. Hélio Amante Miot (UNESP, Brazil) and published in the International Journal of Dermatology (Vol 64, Issue 3, pp. 499–512) — used DELPHI methodology with 9 experts from 9 countries to establish updated guidelines. Cestari et al. (JEADV, 2009) found melasma prevalence of approximately 10% across Latin American populations generally, with rates reaching 50–80% among pregnant Latinas. A 2024 Brazilian survey found facial melasma in 36.3% of respondents.

Hormonal Triggers

Pregnancy is the most common trigger — so common that melasma is sometimes called “the mask of pregnancy,” affecting approximately 50% of pregnant women. But oral contraceptives and hormone replacement therapy (HRT) are equally potent triggers, with melasma developing in 30–50% of oral contraceptive users and 10–30% of HRT users. A 2025 paper in MDPI International Journal of Molecular Sciences detailed the mechanism: estrogen and progesterone activate melanocyte activity through the GPER (G protein-coupled estrogen receptor) pathway, particularly when combined with UV exposure — creating a hormonal-UV feedback loop that perpetuates the condition.

The UV-Melanin Cascade

In melasma-affected skin, melanocytes are hypersensitive to UV radiation. Even brief sun exposure triggers a cascade: UV activates p53, which stimulates α-MSH production, binding to MC1R receptors, activating MITF, and ultimately upregulating tyrosinase — the enzyme that drives melanin synthesis. The patches darken. This is why melasma worsens in summer and improves in winter for women in temperate climates — but for women living in Panama City, Bogota, or Quito, there is no winter reprieve. UV exposure is constant and intense year-round, making sun protection not just helpful but essential to any treatment protocol.

Why Harsh Treatments Make It Worse

High-concentration chemical peels, ablative lasers, and aggressive exfoliation all cause inflammation. In normal skin, that inflammation heals without lasting effect. In melasma-prone skin, inflammation directly stimulates melanocytes — producing more pigment, not less. Hydroquinone, while effective at standard concentrations, carries a risk of ochronosis — a paradoxical darkening — when used at concentrations of 6–12% or continuously for more than 4–5 months (PMC10723018, 2023). Aggressive treatments can convert epidermal melasma (treatable) into dermal melasma (much harder to treat) by pushing pigment deeper into the skin.

The Gold-Standard Approach

The current evidence-based gold standard for melasma treatment, as confirmed by the 2025 Latin American Consensus (Ocampo-Candiani et al.), is a three-pronged approach:

Triple combination cream — hydroquinone 4%, tretinoin 0.05%, and fluocinolone 0.01%. This remains the most effective topical treatment. However, it requires cycling on and off to prevent side effects, particularly the ochronosis risk with prolonged hydroquinone use.

Oral tranexamic acid — increasingly backed by evidence. A 2024 systematic review in the Journal of Dermatological Treatment confirmed that low-dose oral tranexamic acid (250mg twice daily) significantly reduces melasma severity scores with minimal side effects. It works by inhibiting plasmin activity, which reduces melanocyte stimulation. Dr. Seemal Desai has published extensively on optimizing TXA protocols for skin of color (PubMed 37026889).

Rigorous broad-spectrum SPF 50+ — applied daily, reapplied every 2 hours during sun exposure, rain or shine. Studies show that melasma patients using tinted sunscreens (containing iron oxide) see better results than clear sunscreens alone, because iron oxide blocks visible light — which can also stimulate melanocytes.

Why Identification Matters Before Treatment

The treatment that resolves PIH quickly — vitamin C, niacinamide, gentle exfoliation — won’t touch melasma. The treatment that fades sun damage — high-concentration retinoids, IPL — can make melasma worse. Dr. Thierry Passeron (University of Nice), a leading researcher on visible light and melanocyte biology, has published extensively on how misdiagnosis leads to mistreatment, particularly in women with darker skin tones where multiple types of hyperpigmentation often coexist. Getting the identification right isn’t just helpful — it determines whether your treatment heals or harms.

Tracking Progress Between Dermatologist Visits

Melasma is a chronic condition. It doesn’t resolve with a single treatment — it requires ongoing management, monitoring, and adjustment. Skin Scan tracks your melasma over time with before-and-after comparisons, giving you and your dermatologist a visual record of how your skin responds to treatment across weeks and months.

Instead of relying on memory at your next appointment — “I think it’s better? Maybe?” — you arrive with a documented timeline. Your dermatologist can see exactly when the patches lightened, when they darkened again, and correlate those changes with your treatment protocol, hormonal cycle, or sun exposure patterns.